Balyasny Asset Management L.P. Acquires 7.4% Stake in Contineum Therapeutics, Inc.

Balyasny Asset Management L.P. (BAM) has filed a Schedule 13G indicating a significant new ownership stake in Contineum Therapeutics, Inc. (CTNM). As of March 31, 2026, the reporting persons, including BAM, BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, collectively beneficially own 2,417,723 shares of Class A common stock. This position represents approximately 7.4% of the company's outstanding shares. The shares are held directly by Atlas Diversified Master Fund, Ltd. (ADMF), for which BAM serves as the investment manager. Consequently, BAM and its associated entities and individuals may be deemed to exercise voting and investment power over these securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This filing marks a substantial increase from a previous ownership of 0%, establishing Balyasny Asset Management as a major institutional shareholder in the San Diego-based biotechnology firm.